Endocrinology and metabolism Archives - Page 5 of 6

The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus

Authors: M Charokopou, P McEwan, S Lister, L Callan, K Bergenheim, K Tolley, R Postema, R Townsend, M Roudaut Published: Diabetic Medicine, 2015 View publication The cost-effectiveness of dapagliflozin versus sulfonylurea as...

Economic burden of opioid-induced constipation among long-term opioid users with noncancer pain.

Authors: Y Wan, S Corman, X Gao, S Liu, H Patel, R Mody Published: American Health and Drug Benefits, 2015 View publication Background Opioid-induced constipation (OIC) can be a debilitating side effect...

Cost-effectiveness analysis of rivaroxaban in the secondary prevention of acute coronary syndromes in Sweden

Authors: N Begum, S Stephens, O Schoeman, A Fraschke, B Kirsch, J B Briere, F W Verheugt, B van Hout Published: Cardiology and Therapy, 2015 View publication Background Worldwide, coronary heart disease...

Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.

Authors: L H Chuang, B Verheggen, M Charokopou, D Gibson, S Grandy, B Kartman Published: Journal of Medical Economics, 2016 View publication Objective To assess the cost-effectiveness of exenatide 2?mg once-weekly (EQW)...

Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013

Authors: M Charokopou, F J Sabater, R Townsend, M Roudaut, P McEwan, B G Verheggen Published: Current Medical Research and Opinion, 2016 View publication Objective To identify and compare health-economic models that...

Epidemiology of urinary tract infections in type 2 diabetes mellitus patients: an analysis based on a large sample of 456,586 German T2DM patients

Authors: T Wilke, B Boettger, B Berg, A Groth, S Mueller, M Botteman, S Yu, A Fuchs, U Maywald Published: Journal of Diabetes Complications, 2015 View publication Introduction This analysis was conducted...

Economic impact of using fesoterodine for the treatment of overactive bladder with urge urinary incontinence in a vulnerable elderly population in the United States.

Authors: L Qin, X Luo, K H Zou, S J Snedecor Published: Journal of Medical Economics, 2016 View publication Objective To assess the costs of treating overactive bladder (OAB) with fesoterodine compared...

Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the treatment of type 2 diabetes mellitus from a UK Healthcare system perspective

Authors: M Charokopou, P McEwan, S Listers, L Callan, K Bergenheim, K Tolley, R Postema, R Townsend, M Roudaut Published: BMC Health Services Research, 2015 View publication Background Type 2 diabetes mellitus...

Evaluating drug cost per response with SGLT2 inhibitors in patients with type 2 diabetes mellitus

Authors: J M Lopez, B Macomson, V Ektare, D Patel, M Botteman Published: American Health and Drug Benefits, 2015 View publication Background The sodium-glucose cotransporter 2 (SGLT2) inhibitors, which include canagliflozin, dapagliflozin,...

News